亚伯氏症候群（AS）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

市场概览

• 法国市场预计将从约 170 万美元成长到约 230 万美元（年复合成长率约 3%）。
• 儘管由于缺乏疾病修正治疗导致成长仍然有限，但正在研发中的创新正在推动未来的成长潜力。

亚伯氏症候群概述

亚伯氏症候群是一种罕见的、进行性遗传基底膜疾病，由编码IV型胶原蛋白α-3、α-4和α-5链的COL4A3、COL4A4或COL4A5基因的致病突变所引起。此疾病最常见的遗传模式为X连锁遗传，导致肾丝球基底膜（GBM）、耳蜗和眼部组织出现结构缺陷。

胶原蛋白网络的破坏会导致一组特征性的三联征：进行性感音性听障、眼部异常（尤其是前部晶状体锥体）和血尿性肾臟病。肾臟疾病始于镜下血尿和蛋白尿，并随着时间的推移进展至末期肾功能衰竭（ESRD）。

诊断方法正从传统的切片检查观察（例如肾小球基底膜分层和「篮状」有丝分裂）转向分子遗传学检测。目前尚无针对潜在基因缺陷的治疗方法，治疗主要集中于早期使用肾素-血管紧张素-醛固酮系统阻断剂（血管紧张素转换酶抑制剂/血管紧张素受体阻断剂）进行肾臟保护，并越来越多地使用SGLT2抑制剂来延缓肾功能进展。针对纤维化和内皮素路径的新治疗方法目前正在研究中。

主要亮点

• 亚伯氏症候群是一种进行性的、遗传性的肾臟疾病，会影响多个器官。
• 预计法国患有该疾病的人数将从约 9,800 人增加到约 12,300 人（年均复合成长率约 2.3%）。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Enyo Pharma
• Calliditas Therapeutics AB
• Eloxx Pharmaceuticals, Inc.
• Biogen
• Bayer
• River 3 Renal Corp.
• Novartis Pharmaceuticals

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要治疗方法概述及KOL洞察
• 新兴治疗方法
  • 重点
  • 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
  • 值得关注的早期研发管线

第六章：未满足的需求与TPP分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Alport Syndrome Market Outlook

Thelansis's "Alport Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alport Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Alport Syndrome Overview

Alport syndrome is a rare, progressive hereditary disorder of basement membranes caused by pathogenic mutations in the COL4A3, COL4A4, or COL4A5 genes, which encode the alpha-3, alpha-4, and alpha-5 chains of type IV collagen. The disease most commonly follows an X-linked inheritance pattern, leading to structural defects in the glomerular basement membrane (GBM), cochlea, and ocular tissues.

This disruption of the collagen network results in a characteristic clinical triad of progressive sensorineural hearing loss, ocular abnormalities (notably anterior lenticonus), and hematuric nephropathy. The renal disease progresses from microhematuria and proteinuria to end-stage renal disease (ESRD) over time.

Diagnosis has shifted toward molecular genetic testing, replacing traditional renal biopsy findings such as GBM lamellation and "basket-weave" splitting. Currently, there are no therapies that correct the underlying genetic defect, and management focuses on early nephroprotection, primarily through RAAS blockade (ACE inhibitors/ARBs), with increasing use of SGLT2 inhibitors to delay renal progression. Emerging therapies targeting fibrosis and endothelin pathways are under investigation.

Key Highlights

• Alport syndrome is a rare, progressive genetic renal disorder with multisystem involvement
• France prevalence expected to increase from ~9.8K to ~12.3K (~2.3% CAGR)

Market Overview

• France market projected to grow from ~$1.7M to ~$2.3M (~3% CAGR)
• Growth remains limited due to lack of disease-modifying therapies, with pipeline innovation driving future potential

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Enyo Pharma
• Calliditas Therapeutics AB
• Eloxx Pharmaceuticals, Inc.
• Biogen
• Bayer
• River 3 Renal Corp.
• Novartis Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)